Please use this identifier to cite or link to this item:
Title: Therapeutic use of mesenchymal stem cell-derived exosomes: From basic science to clinics
Authors: Harrell C.
Jovicic, Nemanja
Djonov, Valentin
Volarevic, Vladislav
Journal: Pharmaceutics
Issue Date: 1-May-2020
Abstract: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. Mesenchymal stem cells (MSC) are, due to their immunosuppressive and regenerative properties, used as new therapeutic agents in cell-based therapy of inflammatory and degenerative diseases. A large number of experimental and clinical studies revealed that most of MSC-mediated beneficial effects were attributed to the effects of MSC-sourced exosomes (MSC-Exos). MSC-Exos are nano-sized extracellular vesicles that contain MSC-derived bioactive molecules (messenger RNA (mRNA), microRNAs (miRNAs)), enzymes, cytokines, chemokines, and growth factors) that modulate phenotype, function and homing of immune cells, and regulate survival and proliferation of parenchymal cells. In this review article, we emphasized current knowledge about molecular and cellular mechanisms that were responsible for MSC-Exos-based beneficial effects in experimental models and clinical trials. Additionally, we elaborated on the challenges of conventional MSC-Exos administration and proposed the use of new bioengineering and cellular modification techniques which could enhance therapeutic effects of MSC-Exos in alleviation of inflammatory and degenerative diseases.
Type: Review
DOI: 10.3390/pharmaceutics12050474
SCOPUS: 85085965213
Appears in Collections:Faculty of Medical Sciences, Kragujevac
[ Google Scholar ]

Page views(s)


Files in This Item:
File Description SizeFormat 
10.3390-pharmaceutics12050474.pdf1.71 MBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.